ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY
Authors:
MUDr. Miroslav Záleský; Doc. MUDr. Roman Zachoval, Ph.D.; MUDr. Petr Nencka; MUDr. Viktor Vik; MUDr. Vladislav Klemenc
Authors‘ workplace:
Urologické oddělení FTN
Published in:
Urol List 2007; 5(3): 62-68
Overview
The growing rate of detection of prostate cancer in its localised stage has resulted in a growing number of radical prostatectomies performed and in a growing relevance of subsequent complications affecting the patients' quality of life. Erectile dysfunction is one of the most frequent complications of radical prostatectomy (ED). The objective of this overview is to summarise information concerning the incidence, causes, prevention and treatment of erectile dysfunction following radical prostatectomy (RP).
References to key words ”erectile dysfunction, radical prostatectomy“ were searched in the Medline database. Information obtained from the respective sources was used as a basis for this work.
The incidence of ED following RP primarily depends on the age, pre-surgical condition of the patient's erection and the surgical technique applied. The cause of ED following RP is damage or temporary neurapraxy of nervous filaments in the neurovascular bundles (NVB) passing laterodorsally in close vicinity of the prostate. Protracted neurapraxy provokes changes in the cavernous bodies, which causes further deterioration in ED. The incidence of ED following RP can be influenced by the application of nerve-saving surgical techniques and by different measures taken prior to and after the surgery. Among the treatment options for ED following RP is oral treatment with 5-phpsphpdiesterase inhibitors, intracavernous injection therapy, vacuum pump therapy and intraurethral alprostadil therapy. Penile implant surgery is the method of choice for ED following RP to which the above therapies cannot be applied.
Bilateral or unilateral nerve-saving surgery is the basis for prevention of erectile dysfunction following RP. Recently published works on ED following RP point out prophylactic measures reducing the incidence of ED, and the need for early initiation of therapy that may prevent ED from developing into its final stage involving cavernous body fibrosis.
Key words:
prostate carcinoma, radical prostatectomy, erectile dysfunction
Sources
1. Ústav zdravotnických informací a statistiky čR. www.uzis.cz.
2. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
3. Moul JW, Wu H, Sun L et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002; 132: 213-219.
4. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-551.
5. Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. Jama 2000; 283: 354-360.
6. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128: 492-497.
7. Walsh PC, Mostwin JL. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 1984; 56: 694-697.
8. Nandipati KC, Raina R, Agarwal A et al. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. Drugs Aging 2006; 23: 101-117.
9. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802-1807.
10. Hu JC, Elkin EP, Pasta DJ et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171: 703-707.
11. Penson DF, McLerran D, Feng Z et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005; 173: 1701-1705.
12. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 1063-1068.
13. Moreland RB, Traish A, McMillin MA et al. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826-834.
14. Podlasek CA, Gonzalez CM, Zelner DJ et al. Analysis of NOS isoform changes in a post radical prostatectomy model of erectile dysfunction. Int J Impot Res 2001; 13(suppl 5): S1-15.
15. User HM, Hairston JH, Zelner DJ et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003; 169: 1175-1179.
16. Leungwattanakij S, Bivalacqua TJ, Usta MF et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003; 24: 239-245.
17. Iacono F, Giannella R, Somma P et al. Histological alterations in cavernous tissue after radical prostatectomy. J Urol 2005; 173: 1673-1676.
18. Raina R, Agarwal A, Ausmundson S et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18: 77-81.
19. Mulhall JP, Slovick R, Hotaling J et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 2002; 167: 1371-1375.
20. Polascik TJ, Walsh PC. Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function. J Urol 1995; 154: 150-152.
21. McCullough AR. Sexual dysfunction after radical prostatectomy. Rev Urol 2005; 7(suppl 2): S3-S10.
22. Montorsi F, Briganti A, Salonia A et al. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004; 45: 123-133.
23. Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol 2004; 171: 495-500.
24. Donatucci CF, Greenfield JM. Recovery of sexual function after prostate cancer treatment. Curr Opin Urol 2006; 16: 444-448.
25. Heidenreich A, Aus G, Abbou CC et al. Guidelines on Prostate Cancer: European Asociation of Urology Guidelines. Arnhem: EAU 2007.
26. Graefen M, Haese A, Pichlmeier U et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001; 165: 857-863.
27. Graefen M, Walz J, Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006; 49: 38-48.
28. Ohori M, Kattan MW, Koh H et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004; 171: 1844-1849.
29. Walsh PC. Anatomic radical retropubic prostatectomy. In: Walsh PC, Retik AB, Vaughan ED et al. (eds). Campbell´s Urology. Philadelphia: Saunders 2002.
30. Stolzenburg JU, Rabenalt R, Do M et al. Nerve-sparing endoscopic extraperitoneal radical prostatectomy: University of Leipzig technique. J Endourol 2006; 20: 925-929.
31. Rassweiler J, Wagner AA, Moazin M et al. Anatomic nerve-sparing laparoscopic radical prostatectomy: comparison of retrograde and antegrade techniques. Urology 2006; 68: 587-591.
32. Gill IS, Ukimura O, Rubinstein M et al. Lateral pedicle control during laparoscopic radical prostatectomy: refined technique. Urology 2005; 65: 23-27.
33. Curto F, Benijts J, Pansadoro A et al. Nerve sparing laparoscopic radical prostatectomy: our technique. Eur Urol 2006; 49: 344-352.
34. Menon M, Shrivastava A, Kaul S et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol 2007; 51: 648-657.
35. Weldon VE. Technique of modern radical perineal prostatectomy. Urology 2002; 60: 689-694.
36. Weldon VE, Tavel FR, Neuwirth H. Continence, potency and morbidity after radical perineal prostatectomy. J Urol 1997; 158: 1470-1475.
37. Mulhall JP. Cavernous nerve stimulation and interposition grafting: a critical assessment and future perspectives. Rev Urol 2005; 7(suppl 2): S18-25.
38. Lue TF, Gleason CA, Brock GB et al. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. J Urol 1995; 154: 1426-1428.
39. Klotz L, Herschorn S. Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. Urology 1998; 52: 537-542.
40. Klotz L, Heaton J, Jewett M et al. A randomized phase 3 study of intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. J Urol 2000; 164: 1573-1578.
41. Walsh PC, Marschke P, Catalona WJ et al. Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. Urology 2001; 57: 491-494.
42. Quinlan DM, Nelson RJ Walsh PC. Cavernous nerve grafts restore erectile function in denervated rats. J Urol 1991; 145: 380-383.
43. Kim ED, Scardino PT, Hampel O et al. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol 1999; 161: 188-192.
44. Scardino PT, Kim ED. Rationale for and results of nerve grafting during radical prostatectomy. Urology 2001; 57: 1016-1019.
45. Kim ED, Nath R, Slawin KM et al. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology 2001; 58: 983-987.
46. Walsh PC. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. Urology 2001; 57: 1020-1024.
47. Montorsi F, Guazzoni G, Strambi LF et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408-1410.
48. Daley JT, Brown ML, Watkins T et al. Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. J Urol 1996; 155: 1482-1487.
49. Mulhall J, Land S, Parker M et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2: 532-540.
50. Gontero P, Fontana F, Bagnasacco A et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003; 169: 2166-2169.
51. Zagaja GP, Mhoon DA, Aikens JE et al. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000; 56: 631-634.
52. Dall'era JE, Mills JN, Koul HK et al. Penile rehabilitation after radical prostatectomy: important therapy or wishful thinking? Rev Urol 2006; 8: 209-215.
53. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep 2004; 5: 467-471.
54. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171: 771-774.
55. Gallo L, Perdona S, Autorino R et al. Recovery of erection after pelvic urologic surgery: our experience. Int J Impot Res 2005; 17: 484-493.
56. Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 1999; 11(suppl 1): S15-22.
57. Zippe CD, Jhaveri FM, Klein EA et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241-245.
58. Raina R, Lakin MM, Agarwal A et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63: 960-966.
59. Raina R, Lakin MM, Agarwal A et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003; 62: 110-115.
60. Briganti A, Salonia A, Gallina A et al. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2005; 2: 239-247.
61. Brock G, Nehra A, Lipshultz LI et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278-1283.
62. Nehra A, Grantmyre J, Nadel A et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005; 173: 2067-2071.
63. Montorsi F, Nathan HP, McCullough A et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036-1041.
64. Gontero P, Fontana F, Zitella A et al. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. BJU Int 2005; 95: 359-365.
65. Raina R, Lakin MM, Thukral M et al. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2003; 15: 318-322.
66. Raina R, Lakin MM, Agarwal A et al. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004; 63: 532-537.
67. Raina R, Agarwal A, Allamaneni SS et al. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 2005; 65: 360-364.
68. Raina R, Agarwal A, Ausmundson S et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2005; 17: 86-90.
69. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000; 38: 30-34.
70. Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95: 843-846.
71. Khoudary KP, DeWolf WC, Bruning CO 3rd et al. Immediate sexual rehabilitation by simultaneous placement of penile prosthesis in patients undergoing radical prostatectomy: initial results in 50 patients. Urology 1997; 50: 395-399.
72. Ramsawh HJ, Morgentaler A, Covino N et al. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol 2005; 174: 1395-1398.
73. Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol 2006; 16: 186-195.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2007 Issue 3
Most read in this issue
- ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY
- Dihydrotestosterone and inhibitors of steroid 5α-REDUCTASE
- MALE CONTRACEPTION
- Is testosterone supplementation a potential risk for the prostate gland of an ageing male?